For the full article, please click here.
Neuro-Bio Ltd. has identified a peptide derived from AChE — the enzyme responsible for breaking down acetylcholine — and believes the fragment is the main pathological driver in Alzheimer’s disease, acting upstream of β-amyloid and tau in the brain centers hit earliest in the disease.
Neuro-Bio Ltd are delighted to announce that we have been short listed for the BioNewsRound Award. Our CEO, Susan Greenfield will be presenting a short presentation at the ON Helix Welcome Reception on 27th June. You can find out more information on their website, here.
Published in In VivoBeyond Beta-AmyloidThe US FDA has approved six drugs to treat Alzheimer’s symptoms, all of which work by increasing the amount of neurotransmitters in the brain, helping nerve cells in the brain to communicate. These approved therapies are: Razadyne (galantamine), Exelon (rivastigmine), Aricept, Namenda,Namzaric (memantine + donepezil) and Cognex, which is no longer widely sold in the US. None of these drugs prevent or treat the cause of Alzheimer’s, nor do they slow progression of the disease.
Dr Sara Garcia-Rates left Neuro-Bio Ltd in January 2016 on Maternity leave. Neuro-Bio would like to congratulate her and her husband, and wish them the very best of luck to becoming parents. Dr Garcia-Rates will be returning to Neuro-Bio Ltd in July 2016.